# FIGURES





FIG. 1A





FIG. 1B





FIG. 1C





FIG. 1D





FIG. 1E





FIG. 1F





FIG. 1G FIG. 1H





FIG. 1I FIG. 1J FIG. 1K





FIG. 1L FIG. 1M FIG. 1N





FIG. 2



Percent Cytotoxic
120.00
100.00
80.00
60.00
40.00
20.00
0.00
0.001
0.010
0.100
1.000
10.000
100.000
Concentration (μM)
Parent molecule (A549)
Parent molecule (NHDF)
PDC (A549)
PDC (NHDF)

FIG. 3



0.005
0.05
0.5
5
10
50
A375 / HEK293 Ratio
Fold Increase
30
25
20
15
10
5
0
-5
0
0.5
1
6
24
Hours

FIG. 4




FIG. 5



CLR1501
Lipid raft
CLR1501 + Lipid rafts
MM.1S 1501
MM.1R 1501
RPMI8226 1501
U266 1501
H929 1501

FIG. 6



Astrocytes
Neural Stem Cells (NSC)
Glioblastoma Stem-like Cells (GSC)
Serum-cultured Glioblastoma Cells (serGBM)
CL01501
50 µm
99 GSC
99 serGBM

FIG. 7



Effect in A549 Cells
Percent Cytotoxic
120.00
100.00
80.00
60.00
40.00
20.00
0.00
0.001
0.010
0.100
1.000
10.000
100.000
Concentration (uM)
FLV-3 (Lung Cancer)
FLV-3 (NHDF)
CLR 1852 (Lung cancer)
CLR 1852 (NHDF)

FIG. 8



Activity in HCT 116 Tumor Model
Vehicle
CLR 1852 1mg/kg
(3 doses)
Tumor Volume
2500.00
2000.00
1500.00
1000.00
500.00
0.00
6
10
13
17
20
24
27
31
34
38
Days

FIG. 9



Mean Abs Body Weight ± SEM
Vehicle
CLR 1852
Body Weight (g)
35.00
30.00
25.00
20.00
15.00
10.00
5.00
0.00
0
10
20
30
40
50
60
Study Days

FIG. 10



FLV-3 Detected in Cytosolic (Normalized to Cytosolic volume)
Concentration / nM
1200
1000
800
600
400
200
0
A375
A549
0.5 H
1 H
3 H
6 H
24 H
48 H
5
2
67
34
338
318
618
440
879
720
844
645

FIG. 11